Plasma Soluble VEGFR-1 Is a Potential Dual Biomarker of Response and Toxicity for Bevacizumab with Chemoradiation in Locally Advanced Rectal Cancer

DSpace/Manakin Repository

Plasma Soluble VEGFR-1 Is a Potential Dual Biomarker of Response and Toxicity for Bevacizumab with Chemoradiation in Locally Advanced Rectal Cancer

Citable link to this page

 

 
Title: Plasma Soluble VEGFR-1 Is a Potential Dual Biomarker of Response and Toxicity for Bevacizumab with Chemoradiation in Locally Advanced Rectal Cancer
Author: Duda, Dan Gabriel; Willett, Calvin Winslow; Ancukiewicz, M; di Tomaso, E.; Shah, M.; Czito, B. G.; Bentley, R.; Poleski, M.; Lauwers, Gregory Y.; Carroll, M.; Tyler, D.; Mantyh, C.; Shellito, Paul Clarke; Clark, J. W.; Jain, R. K.

Note: Order does not necessarily reflect citation order of authors.

Citation: Duda, D. G., C. G. Willett, M. Ancukiewicz, E. di Tomaso, M. Shah, B. G. Czito, R. Bentley, et al. 2010. “Plasma Soluble VEGFR-1 Is a Potential Dual Biomarker of Response and Toxicity for Bevacizumab with Chemoradiation in Locally Advanced Rectal Cancer.” The Oncologist 15 (6) (May 18): 577–583. doi:10.1634/theoncologist.2010-0029.
Access Status: Full text of the requested work is not available in DASH at this time (“dark deposit”). For more information on dark deposits, see our FAQ.
Full Text & Related Files:
Abstract: We explored plasma and urinary concentrations of two members of the vascular endothelial growth factor (VEGF) family and their receptors as potential response and toxicity biomarkers of bevacizumab with neoadjuvant chemoradiation in patients with localized rectal cancer. The concentrations of VEGF, placental growth factor (PlGF), soluble VEGF receptor 1 (sVEGFR-1), and sVEGFR-2 were measured in plasma and urine at baseline and during treatment. Pretreatment values and changes over time were analyzed as potential biomarkers of pathological response to treatment as well as for acute toxicity in patients with locally advanced rectal cancer treated prospectively in 2002–2008 with neoadjuvant bevacizumab, 5-fluorouracil, radiation therapy, and surgery in a phase I/II trial. Of all biomarkers, pretreatment plasma sVEGFR-1—an endogenous blocker of VEGF and PlGF, and a factor linked with “vascular normalization”—was associated with both primary tumor regression and the development of adverse events after neoadjuvant bevacizumab and chemoradiation. Based on the findings in this exploratory study, we propose that plasma sVEGFR-1 should be further studied as a potential biomarker to stratify patients in future studies of bevacizumab and/or cytotoxics in the neoadjuvant setting.
Published Version: doi:10.1634/theoncologist.2010-0029
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:34268579
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters